The global pharmaceutical industry experienced a 73% drop in company filings mentions of virtual care in Q1 2024 compared with the previous quarter, with the highest share accounted for by Neurocrine Biosciences with 33% year-on-year decrease, according to GlobalData’s analysis of over 40 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q1 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, virtual care was one of the most frequently referenced themes in Q1 2024, ranking highest in terms of mentions, ahead of space economy and environment, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Neurocrine Biosciences had the greatest increase in references for virtual care in Q1 2024, compared with the previous quarter. GlobalData identified two virtual care-related sentences in the company's filings - 0.1% of all sentences - and a decrease of 33% in Q1 2024 compared with Q1 2023.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for virtual care in Q1 2024 was 64.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q1 2024, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.